CDC Guideline for Prescribing Opioids for Chronic Pain

Image of Continuing Education Credits abbreviation.

Date:Wednesday, June 22, 2016

Presenter(s)

Deborah Dowell, MD, MPH
Senior Medical Advisor
Division of Unintentional Injury Prevention
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention

Tamara Haegerich, PhD
Deputy Associate Director for Science
Division of Unintentional Injury Prevention
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention

David J. Tauben, MD, FACP
Chief, Division of Pain Medicine
Clinical Professor
Hughes M & Katherine G Blake Endowed Professor
Departments of Medicine and Anesthesia & Pain Medicine
University of Washington

Overview

The amount of opioids prescribed in the U.S. quadrupled from 1999-2014. Unfortunately, opioid-related overdose deaths have increased in parallel with prescribing increases, and the amount of pain that patients report remains unchanged. The CDC Guideline for Prescribing Opioids for Chronic Pain provides recommendations for safer and more effective prescribing of opioids for chronic pain in patients 18 and older in outpatient settings outside of active cancer treatment, palliative care, and end-of-life care. During this COCA Call, clinicians will hear an overview of the CDC recommendations and learn when and how opioids should be initiated for chronic pain, how to assess risk and address harms of opioid use, and when and how opioids should be discontinued.

Objectives

Describe what is known about effectiveness and risks of long-term opioid therapy for chronic pain.
Discuss how to determine when opioids should be initiated or continued for chronic pain, and when should they be discontinued.
Discuss recommendations for opioid selection and dosage for chronic pain.
Describe strategies that can be used to assess risk and address harms of opioid use.

Call Materials

Slides: View Now
Transcript: Read Now
Audio: Listen Now
Webcast: Watch Now

Additional Resources

CDC Guideline for Prescribing Opioids for Chronic Pain and Related Materials

CDC Vital Signs

CDC Vital Signs: Opioid Painkiller Prescribing – Where You Live Makes a Difference

CDC Injury Prevention and Control

Other Agency Resources

Call Format

Audio conference call on 6/22/16: 2:00 - 3:00 PM EST
Web-on-demand training after 3:00 PM EST on 6/22/16
Materials: PowerPoint slide set

Accreditation Statements

Continuing Education expanded

Activity number:WCWD2286(SC)
Date of origination:December 12, 2013
Date of renewal:December 12, 2015
Date of expiration:December 12, 2017
Prerequisites:None
To earn continuing education/contact hours

Target Audience collapsed

Hardware/Software collapsed

Additional Information collapsed

Accreditation Statements

CME:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE:The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides 1.0 contact hour.

IACET CEU:The Centers for Disease Control and Prevention is authorized by IACET to offer 1.0 CEU's for this program.

CECH:Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

CPE:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is0387-0000-16-148-L04-P and enduring 0387-0000-16-148-H04-P course category.

Course Category: This activity has been designated as knowledge-based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

AAVSB/RACE:This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education in the jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE Program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.

CDC is an approved provider of CPH Recertification Credits by the National Board of Public Health Examiners. Effective October 1, 2013, the National Board of Public Health Examiners (NBPHE) accepts continuing education units (CEU) for CPH recertification credits from CDC. Please select CEU as your choice for continuing education when registering for a course on TCEOnline. Learners seeking CPH should use the guidelines provided by the NBPHE for calculating recertification credits. For assistance please contact NBPHE at http://www.NBPHE.org .

There is no cost for this program.

DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC does not accept commercial support.